Lifyorli (relacorilant) is a prescription medication used in combination with chemotherapy to treat advanced ovarian, fallopian tube, or primary peritoneal cancer in adults who have undergone prior treatments.

Unlike conventional therapies, Lifyorli works as a selective glucocorticoid receptor antagonist, helping reduce tumor resistance and enhancing the effectiveness of chemotherapy.

Advanced cancers often present challenges such as resistance and disease progression, impacting treatment outcomes. Therapies like Lifyorli provide an additional approach to improve response in such cases.

Lifyorli is taken orally alongside chemotherapy and is used under physician guidance as part of a combination treatment strategy.